Your browser doesn't support javascript.
loading
Targeting public neoantigens for cancer immunotherapy.
Pearlman, Alexander H; Hwang, Michael S; Konig, Maximilian F; Hsiue, Emily Han-Chung; Douglass, Jacqueline; DiNapoli, Sarah R; Mog, Brian J; Bettegowda, Chetan; Pardoll, Drew M; Gabelli, Sandra B; Papadopoulos, Nicholas; Kinzler, Kenneth W; Vogelstein, Bert; Zhou, Shibin.
Afiliación
  • Pearlman AH; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Hwang MS; Lustgarten Pancreatic Cancer Research Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Konig MF; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
  • Hsiue EH; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Douglass J; Lustgarten Pancreatic Cancer Research Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • DiNapoli SR; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
  • Mog BJ; Genentech, Inc., South San Francisco, CA, USA.
  • Bettegowda C; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Pardoll DM; Lustgarten Pancreatic Cancer Research Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Gabelli SB; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
  • Papadopoulos N; Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Kinzler KW; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Vogelstein B; Lustgarten Pancreatic Cancer Research Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Zhou S; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Nat Cancer ; 2(5): 487-497, 2021 05.
Article en En | MEDLINE | ID: mdl-34676374
ABSTRACT
Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients' tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos de Neoplasias / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Nat Cancer Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos de Neoplasias / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Nat Cancer Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
...